Silence Therapeutics (SLN) Cash from Operations (2024 - 2026)

Silence Therapeutics has disclosed Cash from Operations across 3 years of filings, most recently posting 15600000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 15600000.0, down 26.74% year-over-year; the trailing twelve-month figure through Mar 2026 was 65562000.0 (up 7.41% YoY), and the FY2025 annual result was 62271000.0, up 7.94% from the prior year.
• Cash from Operations came in at 15600000.0 for Q1 2026 at Silence Therapeutics, up from 17271000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 5409000.0 in Q2 2024 to a low of 27481000.0 in Q4 2024.
• The 3-year median for Cash from Operations is 15600000.0 (2026), against an average of 16167888.89.
• Peak annual rise in Cash from Operations reached 57.41% in 2025, while the deepest fall reached 302.74% in 2025.
• Silence Therapeutics' Cash from Operations stood at 27481000.0 in 2024, then surged by 37.15% to 17271000.0 in 2025, then climbed by 9.68% to 15600000.0 in 2026.
• The last three Cash from Operations figures came in at 15600000.0 (Q1 2026), 17271000.0 (Q4 2025), and 10907000.0 (Q3 2025), per Business Quant data.